Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?
作者信息
Lipson David A, Dransfield Mark T, Han MeiLan K
机构信息
GlaxoSmithKline Collegeville, Pennsylvania.
University of Pennsylvania Philadelphia, Pennsylvania.
出版信息
Am J Respir Crit Care Med. 2020 Sep 1;202(5):773-774. doi: 10.1164/rccm.202004-1399LE.
Abstract
摘要
相似文献
1
Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?对苏伊萨的回复：IMPACT研究中的死亡率：被哮喘混淆了？
Am J Respir Crit Care Med. 2020 Sep 1;202(5):773-774. doi: 10.1164/rccm.202004-1399LE.
2
Mortality in IMPACT: Confounded by Asthma?IMPACT研究中的死亡率：受哮喘影响而混淆？
Am J Respir Crit Care Med. 2020 Sep 1;202(5):772-773. doi: 10.1164/rccm.202004-1159LE.
3
Reply to López-Campos : Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect.回复洛佩斯 - 坎波斯：慢性阻塞性肺疾病的三联疗法试验：死亡率效应的方法学考量
Am J Respir Crit Care Med. 2021 Apr 1;203(7):928-929. doi: 10.1164/rccm.202012-4494LE.
4
Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?慢性阻塞性肺疾病的固定三联疗法与生存率。是活得更好、更久，还是两者兼得？
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1463-1464. doi: 10.1164/rccm.202003-0622ED.
5
[Once daily with a powder inhaler].
MMW Fortschr Med. 2015 Jun 11;157(11):66. doi: 10.1007/s15006-015-3225-9.
6
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.乌美溴铵对固定气流阻塞且对沙丁胺醇有可逆性患者的肺功能和症状的影响：一项随机、3 期研究。
Respir Med. 2017 Oct;131:148-157. doi: 10.1016/j.rmed.2017.08.013. Epub 2017 Aug 14.
7
Fluticasone furoate and vilanterol for COPD - authors' reply.糠酸氟替卡松和维兰特罗用于慢性阻塞性肺疾病——作者回复
Lancet Respir Med. 2013 Jul;1(5):e21-2. doi: 10.1016/S2213-2600(13)70125-5. Epub 2013 Jul 8.
8
Effect of triple therapy in patients with asthma-COPD overlap
.三联疗法对哮喘-慢性阻塞性肺疾病重叠综合征患者的疗效
Int J Clin Pharmacol Ther. 2019 Aug;57(8):384-392. doi: 10.5414/CP203382.
9
Authors' reply to 'Safety and tolerability of fluticasone furoate/vilanterol'.作者对“糠酸氟替卡松/维兰特罗的安全性和耐受性”的回复。
Thorax. 2013 Dec;68(12):1165-6. doi: 10.1136/thoraxjnl-2013-203992. Epub 2013 Jul 2.
10
Fluticasone furoate and vilanterol for COPD.糠酸氟替卡松和维兰特罗用于慢性阻塞性肺疾病
Lancet Respir Med. 2013 Jul;1(5):e21. doi: 10.1016/S2213-2600(13)70100-0. Epub 2013 Jul 8.
引用本文的文献
1
How inhaled corticosteroids target inflammation in COPD.吸入性皮质类固醇如何靶向 COPD 中的炎症。
Eur Respir Rev. 2023 Oct 18;32(170). doi: 10.1183/16000617.0084-2023. Print 2023 Dec 31.
本文引用的文献
1
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.氟替卡松维兰特罗/乌美溴铵粉雾剂降低慢性阻塞性肺疾病患者全因死亡率。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC.
2
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.一项使用共悬浮递送技术的布地奈德/格隆溴铵/富马酸福莫特罗三药联合治疗中重度至极重度 COPD 的 III 期研究：ETHOS 研究方案。
Respir Med. 2019 Oct-Nov;158:59-66. doi: 10.1016/j.rmed.2019.08.010. Epub 2019 Aug 22.
3
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.布地奈德/格隆溴铵/富马酸福莫特罗联合混悬液给药技术三联疗法对比慢性阻塞性肺疾病（KRONOS）中的双联疗法：一项双盲、平行分组、多中心、3 期随机对照临床试验。
Lancet Respir Med. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16.
4
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.COPD 患者每日一次单吸入器三联与双联治疗。
N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.
5
Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者在一般实践人群中的慢性阻塞性肺疾病加重的自然史。
Am J Respir Crit Care Med. 2018 Aug 15;198(4):464-471. doi: 10.1164/rccm.201710-2029OC.
6
At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.根源：定义并阻止早期慢性阻塞性肺疾病的进展
Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551. doi: 10.1164/rccm.201710-2028PP.
7
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.一项 COPD 单次三联疗法的 III 期随机对照试验：IMPACT 方案。
Eur Respir J. 2016 Aug;48(2):320-30. doi: 10.1183/13993003.02165-2015. Epub 2016 Jul 13.
8
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.茚达特罗格隆溴铵与沙美特罗氟替卡松治疗 COPD。
N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.
9
Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.慢性阻塞性肺疾病病死率预测比较 GOLD 2007 及 2011 分期系统：一项个体患者资料的汇总分析。
Lancet Respir Med. 2015 Jun;3(6):443-50. doi: 10.1016/S2213-2600(15)00157-5. Epub 2015 May 17.
10
Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population.采用新 GOLD 分类法预测慢性阻塞性肺疾病的临床病程：一项普通人群研究。
Am J Respir Crit Care Med. 2012 Nov 15;186(10):975-81. doi: 10.1164/rccm.201207-1299OC. Epub 2012 Sep 20.
Zotero 插件